0
Clinical Investigations: CYSTIC FIBROSIS |

Efficiency of Pulmonary Administration of Tobramycin Solution for Inhalation in Cystic Fibrosis Using an Improved Drug Delivery System*

David E. Geller, MD; Margaret Rosenfeld, MD, MPH; David A. Waltz, MD; Robert W. Wilmott, MD, FCCP; AeroDose TOBI Study Group
Author and Funding Information

Affiliations: *From The Nemours Children’s Clinic (Dr. Geller), Orlando, FL; University of Washington (Dr. Rosenfeld), Seattle, WA; Harvard University (Dr. Waltz), Boston, MA; and University of Cincinnati (Dr. Wilmott), Cincinnati, OH.,  Currently at St. Louis University, St. Louis, MO.,  The centers and principal investigators of the AeroDose TOBI Study Group are listed in the Appendix.

Correspondence to: David E. Geller, MD, The Nemours Children’s Clinic, 83 W Columbia St, Orlando, FL 32806-1101; e-mail: dgeller@nemours.org


Affiliations: *From The Nemours Children’s Clinic (Dr. Geller), Orlando, FL; University of Washington (Dr. Rosenfeld), Seattle, WA; Harvard University (Dr. Waltz), Boston, MA; and University of Cincinnati (Dr. Wilmott), Cincinnati, OH.,  Currently at St. Louis University, St. Louis, MO.,  The centers and principal investigators of the AeroDose TOBI Study Group are listed in the Appendix.


Chest. 2003;123(1):28-36. doi:10.1378/chest.123.1.28
Text Size: A A A
Published online

Study objectives: To determine whether tobramycin solution for inhalation (TSI) can be administered safely and more efficiently with a new-generation aerosol device, the AeroDose 5.5 RP inhaler (Aerogen; Mountain View, CA) than with the approved PARI LC PLUS nebulizer (PARI Respiratory Equipment; Monterey, CA) with Pulmo-Aide compressor (DeVilbiss Corp; Somerset, PA). Second, we wanted to ascertain which AeroDose-delivered tobramycin dose is equivalent to the standard 300-mg dose administered with the PARI LC PLUS.

Design: Open-label, randomized, multicenter, single-dose, three-period, four-treatment, active- control, crossover trial.

Setting: Nine US cystic fibrosis (CF) centers.

Patients: Fifty-three patients ≥ 12 years of age with a confirmed diagnosis of CF, the ability to expectorate sputum, and FEV1 of ≥ 40% of predicted.

Methods: Subjects inhaled three single doses of TSI at 1-week intervals, as follows: conventional control treatment, 300 mg via the PARI LC PLUS; and two of three experimental treatments, 30, 60, or 90 mg via the AeroDose. FEV1 was measured before and after dosing. After each dose, sputum and serum samples were collected at various intervals for 8 h, and urine was collected for 24 h to estimate lung and systemic tobramycin delivery.

Results: There were no significant differences between treatments in the change in FEV1 30 min after dosing or in the frequency of adverse events. Sputum and serum levels of tobramycin produced by the AeroDose 90-mg dose treatment approximated those achieved with the PARI LC PLUS 300-mg dose treatment. Nebulization times using the AeroDose inhaler were < 50% those of the PARI LC PLUS.

Conclusions: Compared with the standard nebulizer, the AeroDose safely achieved an approximately threefold greater efficiency in the delivery of TSI to the lungs in less than half the time.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543